Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Inotiv, Inc.
  6. News
  7. Summary
    NOTV   US45783Q1004

INOTIV, INC.

(NOTV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Andrew N. Alexander, DVM, Ph.D., MBA, DABT, Joins Inotiv as Vice President, Pharmacology and Toxicology Operations

10/20/2020 | 08:33am EDT

WEST LAFAYETTE, Ind., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (“Inotiv”, the “Company”, “We” or “Our”), doing business as Inotiv, a leading provider of drug discovery and development services, announced today that Andrew N. Alexander, DVM, Ph.D., MBA, DABT, has joined the Company as Vice President, Pharmacology and Toxicology Operations, effective October 19, 2020.

"Andy brings a skillset that will help us grow Inotiv by providing broader expertise to our clients," said Joe Flynn, the Company’s Chief Commercial Officer. "At least as importantly, Andy embraces our core values, especially delivering excellent client experiences. I am excited to work with Andy here at Inotiv."

Don Maul, Sr. Vice President of Surgical Models, added, "Andy has a great deal of experience and considerable expertise not only with pharm/tox studies, but also with designing and supporting studies in the medical device sector, with an emphasis on complex infusion studies."

Prior to joining Inotiv, Dr. Alexander established a reputation as a leader in contract research organizations where he worked in roles of increasing responsibility for more than a decade, providing scientific expertise and study direction to clients. He then founded his own company, Scientific Business Advisors, which provided scientific and regulatory consulting to biopharmaceutical, veterinary, and medical device companies. His credentials and training include a Doctor of Veterinary Medicine, Ph.D. and MBA, and a postdoctoral fellowship in oncology and immunology, all from or at the University of Wisconsin, as well as a surgical internship at the School of Veterinary Medicine at the University of Illinois.

“I am honored to join Inotiv,” said Dr. Alexander. "Being part of a company that is small enough to be flexible and responsive, but large enough to offer a comprehensive suite of services aligns perfectly with my customer service focus."

About the Company

Bioanalytical Systems, Inc., operating as Inotiv, is a pharmaceutical discovery and development company providing contract research services and monitoring instruments to emerging pharmaceutical companies and the world's leading drug development companies and medical research organizations. The Company focuses on developing innovative services supporting its clients’ discovery and development objectives for improved decision-making and accelerated goal attainment. The Company’s products focus on increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Visit inotivco.com  for more information about the Company.

This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, the impact of COVID-19 on the economy, demand for our services and products and our operations, including the measures taken by governmental authorities to address the pandemic, which may precipitate or exacerbate other risks and/or uncertainties and various other market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.     

FOR MORE INFORMATION:Company Contact:
 Beth A. Taylor
 Chief Financial Officer
 Phone: 765.497.8381
 btaylor@inotivco.com

 

Primary Logo


ę GlobeNewswire 2020
All news about INOTIV, INC.
06/08INOTIVá : to be Added to Russell 3000, Russell 2000 Indices
MT
06/07Inotiv Set to Join Russell 3000« Index and Russell 2000« Index
GL
06/02INOTIV, INC.á : Entry into a Material Definitive Agreement, Creation of a Direct..
AQ
05/27INOTIVá : Acquires St. Louis Facility for $4.7 Million; Plans Capacity Expansion
MT
05/27Inotiv Announces Purchase of St. Louis Facility and Plans to Expand Capacity
GL
05/20LABORATORY OF AMERICAá : Labcorp Builds New Bioanalytical Lab in Singapore
MT
05/18INOTIVá : 2nd Qtr 10Q
PU
05/17INSIDER TRENDS : 90-Day Buying Trend Extended with Insider Purchase of Inotiv St..
MT
05/14INOTIVá : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
05/11Kenneth Swart, Ph.D., Joins Inotiv as Vice President, Bioanalytical Sciences ..
GL
More news
Financials (USD)
Sales 2021 80,2 M - -
Net income 2021 -2,26 M - -
Net Debt 2021 - - -
P/E ratio 2021 -170x
Yield 2021 -
Capitalization 484 M 484 M -
Capi. / Sales 2021 6,04x
Capi. / Sales 2022 3,84x
Nbr of Employees 409
Free-Float 62,3%
Chart INOTIV, INC.
Duration : Period :
Inotiv, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INOTIV, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 31,00 $
Last Close Price 30,60 $
Spread / Highest target 1,31%
Spread / Average Target 1,31%
Spread / Lowest Target 1,31%
EPS Revisions
Managers and Directors
NameTitle
Robert Leasure President, Chief Executive Officer & Director
Beth A. Taylor Chief Financial Officer, Secretary & VP-Finance
Gregory C. Davis Chairman
John Gregory Beattie Chief Operating Officer
Richard Allen Johnson Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
INOTIV, INC.0.00%484
MODERNA, INC.89.37%80 944
LONZA GROUP AG16.07%54 601
IQVIA HOLDINGS INC.36.31%47 315
CELLTRION, INC.-24.37%33 588
SEAGEN INC.-13.60%27 797